Market Overview

The Corporate Reputation of Pharma Companies 2017: The Patient Perspective of 81 Italian Patient Groups - AbbVie was Ranked 1st Overall out of 17 Companies in 2017 -


The "The
Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective
of 81 Italian Patient Groups"
report has been added to's

The patient movement is widespread across the Italian peninsula, and
largely community based. Our currently-running survey confirms that the
primary functions of Italian patient groups are to:

  • provide information to patients
  • offer peer support, and
  • represent patients' interests at both a political level, and with
    health professionals.

Thus, information, knowledge, and communication all lie at the heart of
Italian patient-group activities. And it is these latter activities that
Italian patient groups emphasise when discussing how pharma companies
can improve their corporate reputation.

What Italian patient groups said about pharma's corporate
reputation and activities

Over half of Italian patient groups believed pharma to be "Excellent" or
"Good" in 2017 at innovation (51%), and at providing high-quality
products (57%).

Italian patient groups do, however, take a more negative viewpoint than
patient groups worldwide of some of the pharmaceutical industry's other
key activities, notably the provision of patient information, and
transparency in disclosing the details of the funding of healthcare
stakeholders - which, in turn, negatively impacts on Italian patient
groups' perceptions of the pharma industry's integrity. In addition,
Italian patient groups are more negative than patient groups worldwide
about pharma's ability to provide services beyond the pill.

A call for further engagement with pharma

Although Italian patient groups commented on almost every aspect of
pharma activity (to some degree), the dominant theme they expressed was
frustration with pharma's less-than-effective communicational record.
Italian patient groups called for better interaction with pharma. The
comment from the Associazione per la Lotta alla Trombosi e alle malattie
cardiovascolari Onlus (ALT) was a case in point.

The Italian patient groups produced an extensive list as to how they
think pharma companies should improve their communication efforts with
patient groups and patients

Italian patient groups also argued that listening should be part of the
communication process, with pharmaceutical companies needing to spend
more time listening to patients' perspectivesparticularly on issues
related to research and development (as well as on the performance of
treatment, once it is prescribed). A few Italian patient groups felt
that patient/patient-group input into pharmaceutical-company R&D was a
prerequisite if a company wanted to gain itself a good corporate

So, how did the companies perform at corporate reputation in
2017, in the viewpoints of Italian patient groups?

Ranking at corporate reputation is measured by patient groups familiar
with a company. The rankings of the top companies in 2017 were largely
similar to those of 2016.

  • AbbVie was ranked 1st overall out of 17 companies in
    2017. AbbVie was also ranked 1st in 2017 for six of the 12 individual
    indicators of corporate reputation.
  • Roche was ranked overall 2nd. Roche was ranked 1st
    for one of the 12 individual indicators of corporate reputation.
  • Eli Lilly was ranked overall 3rd. Lilly was ranked
    1st for four of the 12 individual indicators of corporate reputation.

The company which was given the biggest improvement in ranking 2016-2017
by Italian patient groups familiar with it was Janssen,
which rose from 16th out of 16 companies in 2016, to 9th out of 17
companies in 2017. Janssen was also ranked 1st in 2017 for one of the 12
individual indicators of corporate reputation.

Companies Featured

  • Abbvie
  • Astrazeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Chiesi
  • Eli Lilly
  • GSK
  • Janssen
  • Menarini
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • Teva

For more information about this report visit

View Comments and Join the Discussion!